Results 61 to 70 of about 957 (170)

Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs

Emerging Infectious Diseases
The US Food and Drug Administration recognizes the unmet medical need for antibacterial drugs to treat serious bacterial diseases caused by resistant pathogens for which effective therapies are limited or lacking.
Mayurika Ghosh, Dmitri Iarikov, Xiaojing (Karen) Qi, Daniel Rubin, Simone Shurland, Avery Goodwin, Xiaohui Wei, Dakshina Chilukuri, Owen McMaster, Terry Miller, Peter Kim, Adam Sherwat   +11 more
doaj   +1 more source

Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii

Frontiers in Cellular and Infection Microbiology
Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion of CRAB infections is high, appropriate treatment ...
Siqin Zhang, Lingfang Di, Yan Qi, Xiang Qian, Siwei Wang   +4 more
doaj   +1 more source

Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 6, Page 386-392, June 2025.
Abstract Introduction Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion β‐lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population.
Jay D. Olivet, Megan Amerson‐Brown, Juan J. Calix, Emma Graffice, Tyson Kilpatrick, Hanna F. Roenfanz, David P. Nicolau, Joseph L. Kuti, Matthew L. Brown   +8 more
wiley   +1 more source

A review of antibiotic safety in pregnancy—2025 update

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.
Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen, Victoria Madonia, Christopher M. Bland, Kayla R. Stover, Lea S. Eiland, Julia Keating, Madeline Lemmon, P. Brandon Bookstaver, as part of the Southeastern Research Group Endeavor (SERGE‐45) research network   +8 more
wiley   +1 more source

Evaluation of sulbactam/durlobactam activity and synergy against highly drug-resistant <i>Acinetobacter baumannii</i> strains. [PDF]

JAC Antimicrob Resist
Abstract Background Acinetobacter baumannii is a bacterial pathogen frequently implicated in healthcare-associated infections, with limited effective treatment options due to widespread antibiotic resistance.
Halim J, Bouzo J, Carabetta VJ.
europepmc   +3 more sources

Synthesis and Evaluation of Carbapenem/Metallo‐β‐Lactamase Inhibitor Conjugates

ChemMedChem, Volume 19, Issue 21, November 4, 2024.
We report the synthesis and evaluation of molecular conjugates that combine a carbapenem antibiotic (meropenem or ertapenem) with a recently reported indole carboxylate scaffold. These hybrids are potent inhibitors of metallo‐β‐lactamases including the clinically relevant NDM‐1 and IMP‐1 enzymes.
Mei‐Ling Gao, Ioli Kotsogianni, Foteini Skoulikopoulou, Nora C. Brüchle, Paolo Innocenti, Nathaniel I. Martin   +5 more
wiley   +1 more source

Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant \u3ci\u3eAcinetobacter baumannii\u3c/i\u3e Infections

, 2023
OBJECTIVE: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant DATA SOURCES: PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam ...
Kale-Pradhan, Pramodini B, Matlob, Andrew, August, Benjamin A   +2 more
core   +1 more source

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.
Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

in a critically ill burn patient: clinical challenges and molecular characterization

, 2023
Background Carbapenem-resistant Acinetobacter baumannii (CRAB) infections are associated with high mortality rates. The optimal treatment regimen for CRAB has not been defined.
Riccardi, Niccolò, Federica Limongi, Tiseo, Giusy, Nicastro, Manuela, Simona Barnini, Valentina Galfo, Barnini, Simona, Giordano, Cesira, Galfo, Valentina, Niccolò Riccardi, Limongi, Federica, Manuela Nicastro, Giusy Tiseo, Leonildi, Alessandro, Cesira Giordano, Alessandro Leonildi, Marco Falcone, Falcone, Marco   +17 more
core   +1 more source

Epidemiology and clinical significance of carbapenemases in Australia: a narrative review

Internal Medicine Journal, Volume 54, Issue 4, Page 535-544, April 2024.
Abstract Carbapenemase‐producing gram‐negative bacteria (CP‐GNB) infections threaten public health with high mortality, morbidity and treatment costs. Although frequencies remain low in Australia (total number of CP‐GNB infections reported was 907 in 2022), blaIMP‐4 has established low levels of endemicity in many states.
Abdullah Tarik Aslan, David L. Paterson
wiley   +1 more source